Quadria Capital featured image
Banking & Finance News Pharmaceutical & Biotech Stories Technology

Healthcare focused PE Quadria Capital raises $595 million Fund

The healthcare-focused private equity fund Quadria Capital closes a massive $595 million second fund – exceeding its $400 million target.

Quadria Capital is an independent healthcare-focused private equity firm that specializes in growth capital investments in small-cap and middle-market companies within the healthcare sector across South and Southeast Asia.

The funds aim to create significant and sustainable shareholder value by supporting strong, professionally run, stable and scalable healthcare organizations to address the critical and undersupplied healthcare needs in Asia. Quadria Capital aims to make a positive, transformative impact in Asia’s healthcare sector, above and beyond significant financial returns for its investors.

“Countries in South and Southeast Asia are home to nearly a third of the world’s population and shoulder almost half of the world’s disease burden. However, they receive just 4% of the global expenditure,” said Dr. Amit Varma, Quadria Capital.

Quadria Capital has announced a new capital amounting to $595 million in its second fund, exceeding its previous fund which is $400 million. The investors include global asset managers, pension funds, sovereign wealth funds, insurance, healthcare corporates and development finance institutions form the US, Europe and Asian countries.

“We are pleased to be supported by like-minded global investors to deliver sustainable impact beyond compelling financial returns,” said Abrar Mir, managing partner of Quadria Capital.

Founded in 2012, the healthcare-focused private equity Fund has already invested in two companies, one if which is India’s AKUMS Drugs & Pharmaceutical. Quadria’s approach to investment is pivoted around the ability to create value by leveraging its network, operating & investing experience and ability to identify & build regional leaders in the Asian healthcare sector.